Colorectal carcinoma (CRC) is the second leading cause of cancer-related death in the
United States in the general population (men and women combined). Epidemiologic data
obtained over the last several decades shows convincing evidence for the efficacy of
nonsteroidal anti-inflammatory drugs (NSAIDs) in the reduction of risk of CRC through the
inhibition of cycloxygenase (COX). Recent research has also demonstrated that
prostaglandin E 2 (PGE 2), a predominant product of COX, plays a critical role in …